Status:
UNKNOWN
Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide
Lead Sponsor:
Fudan University
Conditions:
Diabetic Neuropathic Pain
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Diabetic neuropathic pain is a common clinical manifestation of diabetic neuropathy, which seriously affects the quality of life of patients. The clinical treatment is limited and the curative effect ...
Detailed Description
1\. Diabetic neuropathic pain seriously affects the quality of life, clinical problems are difficult, and new treatment methods are urgently needed. Diabetic neuropathy is one of the most common comp...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 80; The patients were diagnosed as type 2 diabetic neuropathic pain, and the score of pain digital scoring method was more than 3 points; 7-9% of glycosylated hemoglobin had poor blood glucose control.
Exclusion
- Non diabetic neuropathic pain; BMI \< 20kg / m2; There are serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; In the past 1 month, there were acute complications such as diabetic ketoacidosis, lactic acidosis and hyperosmotic coma; Over the past five years, there have been alcoholics and / or psychoactive substances, drug abusers and addicts; Pregnant or lactating women; Unwillingness to cooperate or various factors affecting compliance; Psychopaths; Those who have participated in other clinical projects in the past 1 month.
Key Trial Info
Start Date :
November 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04137328
Start Date
November 30 2019
End Date
November 30 2022
Last Update
October 25 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.